CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.
- Resource Type
- Article
- Source
- Sleep & Breathing; 2020, Vol. 24 Issue 4, p1441-1449, 9p
- Subject
- Language
- ISSN
- 15209512